<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: risks discussed", fill: "#900"},
{source: "2: risks discussed", target: "2: Companys ", fill: "#900"},
{source: "2: Companys ", target: "2: the Securities and Exchange Commission ", fill: "#900"},
{source: "2: the Securities and Exchange Commission ", target: "2: impact on", fill: "#900"},
{source: "2: impact on", target: "2: Companys ", fill: "#900"},
{source: "2: Companys ", target: "2: financial condition", fill: "#900"},
{source: "2: financial condition", target: "2: operations", fill: "#900"},
{source: "2: risks discussed", target: "4: The Companys ", fill: "#008080"},
{source: "4: The Companys ", target: "4: adversely affected", fill: "#008080"},
{source: "4: adversely affected", target: "4: successfully", fill: "#008080"},
{source: "4: successfully", target: "4: compete against", fill: "#008080"},
{source: "4: compete against", target: "4: competitors", fill: "#008080"},
{source: "4: competitors", target: "4: human health care", fill: "#008080"},
{source: "4: human health care", target: "4: products industry", fill: "#008080"},
{source: "4: The Companys ", target: "5: United States ", fill: "#fffacd"},
{source: "5: United States ", target: "5: pharmaceutical", fill: "#fffacd"},
{source: "5: United States ", target: "21: manufacturers", fill: "#ffe135"},
{source: "21: manufacturers", target: "21: the Company ", fill: "#ffe135"},
{source: "21: the Company ", target: "21: challenging", fill: "#ffe135"},
{source: "21: challenging", target: "21: adequate resources", fill: "#ffe135"},
{source: "21: adequate resources", target: "21: such infringement", fill: "#ffe135"},
{source: "21: manufacturers", target: "START_HERE", fill: "#ffe135"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lluís_Companys">Lluís Companys</a></td>
      <td>Lluís Companys i Jover (Catalan pronunciation: [ʎuˈis kumˈpaɲs]; 21 June 1882 – 15 October 1940) was a Spanish politician from Catalonia who served as president of Catalonia from 1934 and during the Spanish Civil War.\nCompanys was a lawyer close to labour movement and one of the most prominent leaders of the Republican Left of Catalonia (ERC) political party, founded in 1931.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Passeig_de_Lluís_Companys,_Barcelona">Passeig de Lluís Companys, Barcelona</a></td>
      <td>Passeig de Lluís Companys (Catalan pronunciation: [pəˈsɛdʒ də ʎuˈis kumˈpaɲs]) is a promenade in the Ciutat Vella and Eixample districts of Barcelona, Catalonia, Spain, and can be seen as an extension of Passeig de Sant Joan. It was named after President Lluís Companys, who was executed in 1940.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Companys,_procés_a_Catalunya">Companys, procés a Catalunya</a></td>
      <td>Companys, procés a Catalunya (Spanish: Companys, proceso a Cataluña) is a 1979 Spanish Catalan drama film directed by Josep Maria Forn, based on the last months of the life of the President of Catalonia, Lluís Companys, in which he shows his detention by the Nazis and his subsequent execution by the Spanish Francoists. It competed in the Un Certain Regard section at the 1979 Cannes Film Festival.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Conxita_Julià">Conxita Julià</a></td>
      <td>Conxita Julià i Farrés (Catalan pronunciation: [kuɲˈʃitə ʒuliˈa j fəˈres]; 11 June 1920 – 9 January 2019), also known as Conxita de Carrasco, was a Catalan woman noted for her dealings with Lluís Companys, President of Catalonia, in the 1930s, and for her poetry. Julià died in January 2019 at the age of 98.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_largest_companies_in_the_United_States_by_revenue">List of largest companies in the United States by revenue</a></td>
      <td>This list comprises the largest companies in the United States by revenue as of 2022, according to the Fortune 500 tally of companies. Retail corporation Walmart has been the largest company in the US by revenue since 2014.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Víctor_Gay_Zaragoza">Víctor Gay Zaragoza</a></td>
      <td>Víctor Gay Zaragoza (born 19 June 1982 in Barcelona, Spain) is a writer, storyteller, trainer and consultant on storytelling. He is author of the essays "Filosofía Rebelde" (Rebel Philosophy), "50 libros que cambiarán tu vida" (50 books that will change your life) and the historical novel "El defensor" (The defender).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Any of the <font color="blue">risks discussed</font>     below, or elsewhere in this Form 10-K or the Company’s other filings with     the Securities and Exchange Commission, could have a material <font color="blue">impact on</font> the     Company’s business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to <font color="blue">the Company </font>or that the     Company currently believes to be <font color="blue">immaterial may also impair</font> the Company’s     business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s business could be <font color="blue"><font color="blue">adversely</font> affected</font> if it is not able to     <font color="blue">successfully</font>  <font color="blue">compete against</font> the <font color="blue">competitors</font> in the <font color="blue">human health care</font>     <font color="blue">products industry</font></td>
    </tr>
    <tr>
      <td>Competitors of the Hyaluronan and Oral Restorative Divisions in the     <font color="blue"><font color="blue">United States</font> </font>and elsewhere are numerous and include major chemical, dental,     medical, and <font color="blue">pharmaceutical</font> companies, as well as smaller specialized firms</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have <font color="blue">substantially</font> greater capital resources,     marketing  experience, and research and <font color="blue">development</font> resources than the     Company</td>
    </tr>
    <tr>
      <td>These <font color="blue">companies may</font> succeed in developing products that are more     <font color="blue">effective than</font> any that have been or may be developed by Lifecore and may     also prove to be more successful than Lifecore in producing and marketing     these products</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Oral Restorative Division </font>is competing     against a number of large established <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In order to increase     sales, the Division may need to <font color="blue">gain market</font> share from its <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that Lifecore will be able to continue to compete     <font color="blue">successfully</font> against these <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Several companies produce <font color="blue">hyaluronan through</font> a <font color="blue">fermentation process</font>,     including Genzyme, Inc, Savient, Fidia SpA, IOLTECH, Kyowa Hakko, Kibun and     Bayer</td>
    </tr>
    <tr>
      <td>In addition, several companies <font color="blue">manufacture</font> hyaluronan by using     <font color="blue">rooster comb extraction methods</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">companies primarily</font> include Anika     Therapeutics, Inc, Genzyme, Inc, Fidia SpA, Pharmacia and Kibun</td>
    </tr>
    <tr>
      <td>The     Company’s <font color="blue">competitors</font> have filed or obtained <font color="blue">patents covering aspects</font> of     <font color="blue">fermentation production</font> or uses of hyaluronan</td>
    </tr>
    <tr>
      <td>These <font color="blue">patents may cover</font> the     same  <font color="blue">applications</font> as the Company’s <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although <font color="blue">the Company </font>    </font>believes that it does not infringe the patents of its <font color="blue">competitors</font>, there can     be no assurance that <font color="blue">the Company </font>will not receive claims of <font color="blue">infringement</font>     <font color="blue">from <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>In addition, negative <font color="blue">announcements</font> regarding any competitor’s products     may  have  a  negative <font color="blue">impact on</font> the public’s perception of the market     potential for all similar products, including the Company’s products</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">product introductions by present</font> or     future <font color="blue">competitors</font> or <font color="blue">future technological</font> or <font color="blue">health care innovations will</font>     not render Lifecore’s products and <font color="blue">processes obsolete</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Lifecore </font>is unable to <font color="blue">successfully</font> protect its <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font> or     if it is unable to maintain a <font color="blue"><font color="blue">competitive</font> technological position</font> in its     <font color="blue">product areas</font>, its business will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>While certain of Lifecore’s patents have been allowed or issued, there     can be no assurance that, to the <font color="blue">extent issued</font>, the Company’s <font color="blue">patents will</font>     <font color="blue">effectively protect</font> its <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>If other <font color="blue"><font color="blue">manufacture</font>rs</font> were     to infringe on its patents, there can be no assurance that <font color="blue">the Company </font>would     be successful in <font color="blue">challenging</font>, or would have <font color="blue">adequate resources</font> to challenge,     such <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Lifecore also relies upon trade secrets, <font color="blue">proprietary</font>     know-how and <font color="blue">continuing technological innovation</font> to develop and maintain its     <font color="blue">competitive</font>  position</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">others will</font> not     <font color="blue">independently</font>  develop such know-how or otherwise obtain access to the     Company’s  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>While  Lifecore’s  employees, temporary staff,     <font color="blue">consultants</font> and <font color="blue"><font color="blue">corporate partners</font> with access</font> to <font color="blue">proprietary</font> information     are required to enter into confidentiality agreements, there can be no     assurance that these <font color="blue">agreements will provide</font> <font color="blue">the Company </font><font color="blue">with adequate</font>     <font color="blue">protection from loss</font> of <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font> or know-how</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [48]Table of Contents                 Under current law, patent <font color="blue">applications</font> in the <font color="blue"><font color="blue">United States</font> </font>are     maintained in secrecy until patents are issued, and patent <font color="blue">applications</font> in     foreign countries are maintained in secrecy for a period after filing</td>
    </tr>
    <tr>
      <td>The     right to a device patent in the <font color="blue"><font color="blue">United States</font> </font>is <font color="blue">attributable</font> to the first     to  invent  the  device,  not  the first to file a <font color="blue">patent application</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">the Company </font>cannot be sure that its products or <font color="blue">technologies</font> do     not <font color="blue">infringe patents</font> that may be granted in the <font color="blue">future pursuant</font> to pending     patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has not received any notices alleging, and     is not aware of, any <font color="blue">infringement</font> by <font color="blue">the Company </font>of any other entity’s     patents relating to the Company’s current or anticipated products</td>
    </tr>
    <tr>
      <td>There can     be no assurance, however, that its products do not infringe any patents or     <font color="blue">proprietary</font> rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In the event that any relevant claims     of third-party patents are upheld as valid and enforceable, <font color="blue">the Company </font>    could be <font color="blue">prevented from selling</font> its products or could be required to obtain     <font color="blue">licenses from</font> the owners of <font color="blue">such patents</font> or be required to redesign its     products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that     such  licenses  would be available or, if available, would be on terms     acceptable to <font color="blue">the Company </font>or that <font color="blue">the Company </font>would be successful in any     attempt to redesign its products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>The     Company’s failure to obtain these licenses or to redesign its products or     <font color="blue">processes would</font> have a material adverse effect on the Company’s business,     <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s business will be <font color="blue"><font color="blue">adversely</font> affected</font> if it is unable to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">new product introductions</font> or to <font color="blue">expand sales</font> of     <font color="blue"><font color="blue">existing products</font> into new markets</font></td>
    </tr>
    <tr>
      <td>The Company’s products under <font color="blue">development</font> are considered to be     <font color="blue">medical devices</font> and, therefore, they require clearance or <font color="blue">approval by</font> the     FDA before <font color="blue">commercial sales</font> can be made in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The products     also require approvals of <font color="blue">foreign <font color="blue">government</font> agencies</font> before sales may be     made in many other countries</td>
    </tr>
    <tr>
      <td>The process of obtaining these <font color="blue">clearances</font> or     <font color="blue">approvals varies according</font> to the nature and use of the product</td>
    </tr>
    <tr>
      <td>It can     <font color="blue">involve lengthy</font> and <font color="blue">detailed laboratory</font> and clinical testing, sampling     <font color="blue">activities</font> and other costly and time-consuming procedures</td>
    </tr>
    <tr>
      <td>There can be no     assurance that any of the required <font color="blue">clearances</font> or <font color="blue">approvals will</font> be granted     on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>In addition, most of the <font color="blue">existing products</font> being sold by the     Company and its customers are subject to continued regulation by the FDA,     various  state agencies and foreign <font color="blue">regulatory</font> agencies which regulate     <font color="blue">manufacturing</font>, labeling and record keeping procedures for <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Marketing </font><font color="blue">clearances</font> or approvals by these agencies can be <font color="blue">withdrawn due</font> to     failure to <font color="blue">comply with <font color="blue">regulatory</font> standards</font> or the occurrence of unforeseen     <font color="blue">problems following initial clearance</font> or approval</td>
    </tr>
    <tr>
      <td>These agencies can also     limit or prevent the <font color="blue">manufacture</font> or <font color="blue">distribution</font> of the Company’s products</td>
    </tr>
    <tr>
      <td>A <font color="blue">determination</font> that <font color="blue">the Company </font>is in violation of <font color="blue">such regulations could</font>     lead to the imposition of <font color="blue">civil penalties</font>, including fines, product recalls     or product seizures, injunctions, and, in extreme cases, criminal sanctions</td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>is  exposed to the risks of operating a global business,     including  risks associated with exchange rate fluctuations, legal and     <font color="blue">regulatory</font>  changes  and  the  impact  of regional and <font color="blue">global economic</font>     <font color="blue">disruptions</font>, which could have an adverse effect on the Company’s business</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">shipments accounted</font> for 49prca of net sales in fiscal     2006</td>
    </tr>
    <tr>
      <td>We expect that international shipments will continue to represent a     <font color="blue"><font color="blue">significant</font> percentage</font> of net sales in the future</td>
    </tr>
    <tr>
      <td>Our non-US sales,     purchases  and  <font color="blue">operations</font> are subject to <font color="blue">risks inherent</font> in conducting     business  abroad, many of which are outside our control, including the     following:       •   Periodic local or <font color="blue">geographic economic downturns</font> and <font color="blue">unstable political</font>     <font color="blue">conditions</font>;         •   Price and currency exchange controls;         •   <font color="blue">Fluctuation </font>in the <font color="blue">relative values</font> of currencies;         •   <font color="blue">Difficulties </font><font color="blue">protecting intellectual property</font>;         •   Local <font color="blue">labor disputes</font>;         •   Shipping delays and <font color="blue">disruptions</font>;          •    <font color="blue">Increases </font>in shipping costs, caused by increased fuel costs or     otherwise, which we may not be able to pass on to our customers;         •   <font color="blue">Unexpected </font>changes in trading policies, <font color="blue">regulatory</font> <font color="blue">requirements</font>,     tariffs and other barriers; and         •   <font color="blue">Difficulties </font>in managing a global enterprise, including staffing,     collecting  <font color="blue">accounts</font>  receivable, managing suppliers, <font color="blue">distributors</font> and     <font color="blue">representatives</font>, and <font color="blue">repatriation</font> of earnings</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [49]Table of Contents                 Our business and operating results are subject to <font color="blue">uncertainties</font>     arising out of the <font color="blue">possibility</font> of regional or <font color="blue">global economic</font> <font color="blue">disruptions</font>     (including  those  resulting  from  <font color="blue">natural disasters</font> and outbreaks of     <font color="blue">infectious</font>  disease),  the <font color="blue">economic consequences</font> of <font color="blue">military action</font> or     terrorist <font color="blue">activities</font> and <font color="blue">associated political instability</font>, and the impact of     heightened  <font color="blue">security concerns on domestic</font> and <font color="blue">international travel</font> and     commerce</td>
    </tr>
    <tr>
      <td>In particular, due to these <font color="blue">uncertainties</font> we are subject to:       •   The risk of more <font color="blue">frequent instances</font> of <font color="blue">shipping delays</font>; and         •   The risk that demand for our <font color="blue">products may</font> not increase or may     decrease</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of new <font color="blue">hyaluronan products</font> entails substantial risk of     failure and <font color="blue">uncertainty</font> related to timing, and a <font color="blue"><font color="blue">significant</font> amount</font> of the     Company’s  anticipated  growth is <font color="blue">dependent on</font> its ability to develop,     <font color="blue">manufacture</font> and <font color="blue">market new product</font> <font color="blue">applications</font> for hyaluronan</td>
    </tr>
    <tr>
      <td>A  <font color="blue"><font color="blue">significant</font> amount</font> of the Company’s anticipated growth is     <font color="blue">dependent on</font> its ability to develop, <font color="blue">manufacture</font> and <font color="blue">market new product</font>     <font color="blue">applications</font> for hyaluronan</td>
    </tr>
    <tr>
      <td>Such formulations must be developed, tested     and, in most cases, approved for <font color="blue">use by appropriate <font color="blue">government</font> agencies</font></td>
    </tr>
    <tr>
      <td>Once  approved  as  products,  they must be <font color="blue">manufacture</font>d in commercial     quantities  and  marketed  <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Each of these steps involves     <font color="blue"><font color="blue">significant</font> amount</font>s of time and expense</td>
    </tr>
    <tr>
      <td>There can be no assurance that any     of these products, if and when fully developed and tested, will perform in     <font color="blue">accordance</font>  with the Company’s <font color="blue">expectations</font>, that <font color="blue">necessary</font> <font color="blue">regulatory</font>     <font color="blue">approvals will</font> be obtained in a <font color="blue">timely manner</font>, if at all, or that these     products can be <font color="blue">successfully</font> and profitably produced and marketed</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">dependent on</font> the marketing and <font color="blue">development</font> support from     <font color="blue">corporate partners</font> for the <font color="blue">sales growth</font> of the Hyaluronan Division, and the     Company’s business could be <font color="blue"><font color="blue">adversely</font> affected</font> if the Company’s strategic     <font color="blue">alliances fail</font> to develop or <font color="blue">market products as</font> planned</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">historically</font> developed, <font color="blue">manufacture</font>d, and marketed     its <font color="blue">Hyaluronan Division </font><font color="blue">products through</font> long-term <font color="blue">strategic alliances</font> with     <font color="blue">corporate partners</font></td>
    </tr>
    <tr>
      <td>In the case of such <font color="blue">relationships</font>, the speed and other     aspects of the <font color="blue">development</font> project are <font color="blue">sometimes outside</font> of the Company’s     control, as the other party to the <font color="blue">relationship often</font> has priorities that     <font color="blue">differ from</font> those of the Company</td>
    </tr>
    <tr>
      <td>Thus, the timing of <font color="blue">commercialization</font> of     the Company’s products under <font color="blue">development</font> may be subject to <font color="blue">unanticipated</font>     delays</td>
    </tr>
    <tr>
      <td>Further,  the  <font color="blue">Company  </font>currently  has  limited <font color="blue">direct sales</font>     <font color="blue">capabilities</font>  in the <font color="blue">Hyaluronan Division </font>and <font color="blue">generally</font> relies upon its     <font color="blue">corporate partners</font> for marketing and <font color="blue">distribution</font> to end-users</td>
    </tr>
    <tr>
      <td>The market     success of the Company’s <font color="blue">hyaluronan products</font> <font color="blue">generally</font> will depend upon the     size and skill of the marketing organizations of the Company’s corporate     partners, as well as the level of <font color="blue">priority assigned</font> to the marketing of the     Company’s <font color="blue">products by</font> these entities, which may <font color="blue">differ from</font> the Company’s     priorities</td>
    </tr>
    <tr>
      <td>Should one or more of the Company’s strategic <font color="blue">alliances fail</font> to     develop  or  <font color="blue">market products as</font> planned, the Company’s business may be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>No assurance can be given that <font color="blue">the Company </font>will be able     to negotiate acceptable <font color="blue">strategic alliances</font> in the future or that current     <font color="blue">strategic alliances</font> will continue</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> contracts into which <font color="blue">the Company </font><font color="blue">enters with</font>     <font color="blue">corporate partners</font> are long-term agreements that are subject to <font color="blue">development</font>     milestones, product specifications, and other terms</td>
    </tr>
    <tr>
      <td>Consequently, future     <font color="blue">agreement often</font> is required regarding the course and nature of continued     <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contractual </font>issues requiring <font color="blue">resolution between</font> the     parties have arisen in the past and are expected to arise in the ordinary     course of the Company’s future <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that all <font color="blue">such issues will</font> be <font color="blue">successfully</font> resolved</td>
    </tr>
    <tr>
      <td>If <font color="blue">the Company </font>is unable to scale up <font color="blue">manufacturing</font> <font color="blue">operations</font> in the event     of a <font color="blue">significant</font> increase in <font color="blue">customer demand</font>, the Company’s business could     be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The  Company has designed its <font color="blue">modular <font color="blue">facility</font></font> to permit the     production of <font color="blue">hyaluronan at levels exceeding current levels</font> of production</td>
    </tr>
    <tr>
      <td>However, in the event of a sudden <font color="blue">significant</font> increase in demand for any of     the Company’s <font color="blue">hyaluronan products</font>, <font color="blue">the Company </font>will be required to scale-up     <font color="blue">operations</font>, including the <font color="blue">acquisition</font> and <font color="blue">validation</font> of <font color="blue">additional equipment</font>     and training of <font color="blue">additional personnel</font></td>
    </tr>
    <tr>
      <td>No assurance can be given that the     Company will be able to <font color="blue">adequately meet</font> any <font color="blue">such demands on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [50]Table of Contents       An <font color="blue">interruption</font> in the Company’s <font color="blue">manufacturing</font> <font color="blue">activities</font> could <font color="blue">adversely</font>     affect the Company’s <font color="blue">relations with</font> its customers</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">manufacturing</font> requires extensive <font color="blue">specialized equipment</font></td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">the Company </font><font color="blue">manufacture</font>s its <font color="blue">hyaluronan products</font> at one     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>has <font color="blue">contingency</font> plans in effect for certain     <font color="blue">natural disasters</font>, as well as other <font color="blue">unforeseen events</font> that could damage the     Company’s <font color="blue">facilities</font> or equipment, no assurance can be given that any such     <font color="blue">events will</font> not <font color="blue">materially interrupt</font> the Company’s business</td>
    </tr>
    <tr>
      <td>In the event of     such an occurrence, <font color="blue">the Company </font>has business <font color="blue">interruption</font> insurance to cover     <font color="blue">lost revenues</font> and profits</td>
    </tr>
    <tr>
      <td>However, <font color="blue">such insurance would</font> not compensate the     <font color="blue">Company  </font>for  the  loss of <font color="blue">opportunity</font> and potential adverse <font color="blue">impact on</font>     <font color="blue">relations with</font> existing customers created by an <font color="blue">inability</font> to produce its     products</td>
    </tr>
    <tr>
      <td>There is <font color="blue">uncertainty</font> and risk that FeHA will not be returned to the market,     <font color="blue">which would negatively impact</font> the Company’s <font color="blue">future revenue potential</font></td>
    </tr>
    <tr>
      <td>FeHA,  (<font color="blue">formerly labeled as</font> GYNECARE INTERGEL Adhesion Prevention     Solution (“INTERGEL Solution”)) was <font color="blue">voluntarily withdrawn from</font> the <font color="blue">market by</font>     ETHICON  in  March 2003  in  order to assess information obtained from     <font color="blue">postmarketing</font> experience with the product, including <font color="blue">allegations</font> of adverse     events associated with off-label use in non-conservative surgical procedures     (<font color="blue">such as hysterectomies</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has completed the post-marketing     <font color="blue">evaluation</font> and shared the results with the FDA <font color="blue">The Company </font>is currently     evaluating  <font color="blue">regulatory</font> <font color="blue">requirements</font> and <font color="blue">opportunities</font> for <font color="blue">distribution</font>     partners for the FeHA product to return to market</td>
    </tr>
    <tr>
      <td>The markets for the Company’s <font color="blue">dental products</font> are very <font color="blue">competitive</font>, and the     Company’s results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be <font color="blue">adversely</font>     affected  if  it cannot maintain or increase the market share of these     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">Oral Restorative Division </font>markets its <font color="blue">products through</font> a direct     <font color="blue">sales force</font> and a <font color="blue">distribution</font> network</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font>growth of the Company’s     revenues from oral restorative products will depend on the ability of this     sales and <font color="blue">distribution</font> network to increase the Company’s market share by     convincing  <font color="blue">practitioners</font> to use the Company’s <font color="blue">products over competing</font>     established  products</td>
    </tr>
    <tr>
      <td>No  assurance  can be given that the sales and     <font color="blue">distribution</font> network will be successful in increasing or maintaining the     Company’s market share or <font color="blue">sales levels</font></td>
    </tr>
    <tr>
      <td>Failure to maintain and increase the     market share of these products would <font color="blue">adversely</font> affect the Company’s results     of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be subject to <font color="blue">product <font color="blue">liability</font></font> claims and other legal     <font color="blue">proceedings which could</font> have a material adverse effect on the Company’s     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of the Company’s <font color="blue">products entails</font> a risk of     <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">product <font color="blue">liability</font></font> exposure for its     own products, <font color="blue">the Company </font>may be subject to claims for products of its     <font color="blue">customers which incorporate</font> Lifecore’s materials</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains     <font color="blue">product <font color="blue">liability</font></font> insurance coverage in amounts it deems adequate</td>
    </tr>
    <tr>
      <td>However,     there can be no assurance that <font color="blue">the Company </font>will have <font color="blue">sufficient resources</font> if     claims <font color="blue">exceed available insurance coverage</font></td>
    </tr>
    <tr>
      <td>In addition, other types of     claims may arise that are not <font color="blue">covered by such insurance</font></td>
    </tr>
    <tr>
      <td>Lifecore was named as a <font color="blue">defendant</font> in 80 <font color="blue">product <font color="blue">liability</font></font> lawsuits, all     of which allege that the <font color="blue">plaintiffs suffered injuries due</font> to the defective     nature  of  INTERGEL Solution <font color="blue">manufacture</font>d by Lifecore and marketed by     <font color="blue">ETHICON During </font>the course of the past year, ETHICON <font color="blue">settled several</font> of the     <font color="blue">lawsuits without seeking</font> any <font color="blue">contribution from</font> Lifecore</td>
    </tr>
    <tr>
      <td>In addition, eight     of  the cases were <font color="blue">voluntarily dismissed</font> and one case was <font color="blue">dismissed on</font>     <font color="blue">summary judgment</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that these pending claims, other new product     <font color="blue">liability</font> claims, claims <font color="blue">with respect</font> to <font color="blue">uninsured liabilities</font> or claims in     excess of insured liabilities, will not have a material adverse effect on     the business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> of the Company</td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that insurance will continue to be     available to <font color="blue">the Company </font>and that, if available, the insurance will continue     to be on <font color="blue">commercially</font> acceptable terms</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [51]Table of Contents       Failure  to maintain effective <font color="blue">internal controls</font> could have a material     adverse effect on the Company’s business, operating results and stock price</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our fiscal 2006 audit, we documented and tested our     internal  control  procedures  in order to satisfy the <font color="blue">requirements</font> of     Section 404 of the Sarbanes-Oxley Act, which requires <font color="blue">annual management</font>     <font color="blue">assessments</font> of the <font color="blue">effectiveness</font> of our <font color="blue"><font color="blue">internal controls</font> over financial</font>     reporting and a report by our <font color="blue">independent registered public accounting firm</font>     <font color="blue">addressing</font> these <font color="blue">assessments</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of our     <font color="blue">internal controls</font>, we may not be able to ensure that we can conclude on an     ongoing  basis that we have effective <font color="blue"><font color="blue">internal controls</font> over financial</font>     reporting  in  <font color="blue">accordance</font>  with Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>Moreover, effective <font color="blue">internal controls</font>, particularly those related to revenue     <font color="blue">recognition</font>, are <font color="blue">necessary</font> for us to produce <font color="blue">reliable financial</font> reports and     are important to <font color="blue">prevent financial fraud</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot provide reliable</font>     financial reports or <font color="blue">prevent fraud</font>, our business and operating results could     be  harmed,  <font color="blue">investors could lose confidence</font> in our reported financial     information, and the <font color="blue">trading price</font> of our stock could drop <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>The Company’s tax rates are subject to fluctuation, which could impact its     <font color="blue">financial position</font>, and its estimates of <font color="blue">tax liabilities may</font> be subject to     audit, which could result in additional <font color="blue">assessments</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">effective tax rates</font> are subject to <font color="blue">fluctuation as</font> the income tax     rates for <font color="blue">each year</font> are a function of: (a) the effects of a mix of profits     (losses) earned  by  <font color="blue">Lifecore  </font>and  its  <font color="blue">subsidiaries</font>  in numerous tax     <font color="blue">jurisdictions</font> with a broad range of income tax rates, (b) our ability to     utilize recorded deferred tax assets, and (c) changes in tax laws or the     <font color="blue">interpretation</font> of <font color="blue">such tax laws</font></td>
    </tr>
    <tr>
      <td>Changes in the mix of these items may cause     our <font color="blue">effective tax rates</font> to fluctuate between periods, which could have a     material adverse effect on our <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">income taxes</font> in both the <font color="blue"><font color="blue">United States</font> </font>and foreign     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>During  the ordinary course of business there are many     <font color="blue">transactions</font> and <font color="blue">calculations</font> for which the ultimate tax <font color="blue">determination</font> is     uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>judgment is exercised in determining our world wide     provisions for <font color="blue">income taxes</font></td>
    </tr>
    <tr>
      <td>The Company’s business could be <font color="blue"><font color="blue">adversely</font> affected</font> if it were to lose the     services of its <font color="blue">key management employees</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">success depends</font> in large part upon the services of its     <font color="blue">executive officers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">executive officers</font> consist of Dennis J Allingham,     President and Chief Executive Officer, David M Noel, Vice President of     Finance and Chief Financial Officer; Larry Hiebert, Vice President and     General Manager of the Hyaluronan Division; Ben Beckham, Vice President of     Sales and <font color="blue">Marketing </font>for the Oral Restorative Division, James G Hall, Vice     President of Technical Operations and Kipling Thacker, Ph</td>
    </tr>
    <tr>
      <td>The loss of any one of these <font color="blue">individuals may</font>     have a material adverse effect on the Company’s business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The     Company does not have <font color="blue">employment agreements with</font> or <font color="blue">life insurance on</font> its     officers</td>
    </tr>
    <tr>
      <td>Market prices for securities of medical <font color="blue">technology</font> companies are highly     volatile, and the <font color="blue">trading price</font> of the Company’s Common Stock is subject to     <font color="blue">significant</font> fluctuations</td>
    </tr>
    <tr>
      <td>Market prices in the <font color="blue"><font color="blue">United States</font> </font>for securities of medical <font color="blue">technology</font>     companies can be highly volatile, and the <font color="blue">trading price</font> of the Company’s     Common Stock could be subject to <font color="blue">significant</font> fluctuations in response to     <font color="blue">quarterly variations</font> in operating results, <font color="blue">announcements</font> of the status or     results of <font color="blue">development</font> projects or <font color="blue">technological innovations by</font> <font color="blue">the Company </font>    or its <font color="blue">competitors</font>, <font color="blue">government</font> regulation and other events or factors</td>
    </tr>
    <tr>
      <td>The     <font color="blue">volatility</font> in <font color="blue"><font color="blue">market price</font>s may</font> be unrelated to the operating performance of     <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">market fluctuations</font> have in the <font color="blue">past materially</font>     <font color="blue"><font color="blue">adversely</font> affected</font> the <font color="blue">market price</font> of the Company’s Common Stock, and may     have such an effect in the future</td>
    </tr>
  </tbody>
</table>